RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment

Raffaele Hellweg, Ashley Mooneyham, Zenas Chang, Mihir Shetty, Edith Emmings, Yoshie Iizuka, Christopher Clark, Tim Starr, Juan E Abrahante - Llorens, Florian Schütz, Gottfried Konecny, Peter A Argenta, Martina Bazzaro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite advances in surgical technique and adjuvant treatment, endometrial cancer has recently seen an increase in incidence and mortality in the USA. The majority of endometrial cancers can be cured by surgery alone or in combination with adjuvant chemo- or radiotherapy; however, a subset of patients experience recurrence for reasons that remain unclear. Recurrence is associated with chemoresistance to carboplatin and paclitaxel and consequentially, high mortality. Understanding the pathways involved in endometrial cancer chemoresistance is paramount for the identification of biomarkers and novel molecular targets for this disease. Here, we generated the first matched pairs of carboplatin-sensitive/carboplatin-resistant and paclitaxel-sensitive/paclitaxel-resistant endometrial cancer cells and subjected them to bulk RNA sequencing analysis. We found that 45 genes are commonly upregulated in carboplatin- and paclitaxel-resistant cells as compared to controls. Of these, the leukemia inhibitory factor, (LIF), the protein tyrosine phosphatase type IVA, member 3 (PTP4A3), and the transforming growth factor beta 1 (TGFB1) showed a highly significant correlation between expression level and endometrial cancer overall survival (OS) and can stratify the 545 endometrial cancer patients in the TCGA cohort into a high-risk and low-risk-cohorts. Additionally, four genes within the 45 upregulated chemoresistance-associated genes are ADAMTS5, MICAL2, STAT5A, and PTP4A3 codes for proteins for which small-molecule inhibitors already exist. We identified these proteins as molecular targets for chemoresistant endometrial cancer and showed that treatment with their correspondent inhibitors effectively killed otherwise chemoresistant cells. Collectively, these findings underline the utility of matched pair of chemosensitive and chemoresistant cancer cells to identify markers for endometrial cancer risk stratification and to serve as a pharmacogenomics model for identification of alternative chemotherapy approaches for treatment of patients with recurrent disease.

Original languageEnglish (US)
Pages (from-to)326-337
Number of pages12
JournalHormones and Cancer
Volume9
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

RNA Sequence Analysis
Carboplatin
Endometrial Neoplasms
Paclitaxel
Neoplasms
Therapeutics
Genes
Leukemia Inhibitory Factor
Recurrence
Adjuvant Radiotherapy
Protein Tyrosine Phosphatases
Mortality
Pharmacogenetics
Adjuvant Chemotherapy
Transforming Growth Factor beta
Proteins
Biomarkers
Drug Therapy
Survival
Incidence

Keywords

  • Chemoresistance
  • Endometrial cancer
  • Gene expression
  • Recurrence

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

Cite this

RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. / Hellweg, Raffaele; Mooneyham, Ashley; Chang, Zenas; Shetty, Mihir; Emmings, Edith; Iizuka, Yoshie; Clark, Christopher; Starr, Tim; Abrahante - Llorens, Juan E; Schütz, Florian; Konecny, Gottfried; Argenta, Peter A; Bazzaro, Martina.

In: Hormones and Cancer, Vol. 9, No. 5, 01.10.2018, p. 326-337.

Research output: Contribution to journalArticle

Hellweg, Raffaele ; Mooneyham, Ashley ; Chang, Zenas ; Shetty, Mihir ; Emmings, Edith ; Iizuka, Yoshie ; Clark, Christopher ; Starr, Tim ; Abrahante - Llorens, Juan E ; Schütz, Florian ; Konecny, Gottfried ; Argenta, Peter A ; Bazzaro, Martina. / RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. In: Hormones and Cancer. 2018 ; Vol. 9, No. 5. pp. 326-337.
@article{89eb7fae98c4410ca7a38948819dcdcf,
title = "RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment",
abstract = "Despite advances in surgical technique and adjuvant treatment, endometrial cancer has recently seen an increase in incidence and mortality in the USA. The majority of endometrial cancers can be cured by surgery alone or in combination with adjuvant chemo- or radiotherapy; however, a subset of patients experience recurrence for reasons that remain unclear. Recurrence is associated with chemoresistance to carboplatin and paclitaxel and consequentially, high mortality. Understanding the pathways involved in endometrial cancer chemoresistance is paramount for the identification of biomarkers and novel molecular targets for this disease. Here, we generated the first matched pairs of carboplatin-sensitive/carboplatin-resistant and paclitaxel-sensitive/paclitaxel-resistant endometrial cancer cells and subjected them to bulk RNA sequencing analysis. We found that 45 genes are commonly upregulated in carboplatin- and paclitaxel-resistant cells as compared to controls. Of these, the leukemia inhibitory factor, (LIF), the protein tyrosine phosphatase type IVA, member 3 (PTP4A3), and the transforming growth factor beta 1 (TGFB1) showed a highly significant correlation between expression level and endometrial cancer overall survival (OS) and can stratify the 545 endometrial cancer patients in the TCGA cohort into a high-risk and low-risk-cohorts. Additionally, four genes within the 45 upregulated chemoresistance-associated genes are ADAMTS5, MICAL2, STAT5A, and PTP4A3 codes for proteins for which small-molecule inhibitors already exist. We identified these proteins as molecular targets for chemoresistant endometrial cancer and showed that treatment with their correspondent inhibitors effectively killed otherwise chemoresistant cells. Collectively, these findings underline the utility of matched pair of chemosensitive and chemoresistant cancer cells to identify markers for endometrial cancer risk stratification and to serve as a pharmacogenomics model for identification of alternative chemotherapy approaches for treatment of patients with recurrent disease.",
keywords = "Chemoresistance, Endometrial cancer, Gene expression, Recurrence",
author = "Raffaele Hellweg and Ashley Mooneyham and Zenas Chang and Mihir Shetty and Edith Emmings and Yoshie Iizuka and Christopher Clark and Tim Starr and {Abrahante - Llorens}, {Juan E} and Florian Sch{\"u}tz and Gottfried Konecny and Argenta, {Peter A} and Martina Bazzaro",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s12672-018-0337-6",
language = "English (US)",
volume = "9",
pages = "326--337",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "5",

}

TY - JOUR

T1 - RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment

AU - Hellweg, Raffaele

AU - Mooneyham, Ashley

AU - Chang, Zenas

AU - Shetty, Mihir

AU - Emmings, Edith

AU - Iizuka, Yoshie

AU - Clark, Christopher

AU - Starr, Tim

AU - Abrahante - Llorens, Juan E

AU - Schütz, Florian

AU - Konecny, Gottfried

AU - Argenta, Peter A

AU - Bazzaro, Martina

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Despite advances in surgical technique and adjuvant treatment, endometrial cancer has recently seen an increase in incidence and mortality in the USA. The majority of endometrial cancers can be cured by surgery alone or in combination with adjuvant chemo- or radiotherapy; however, a subset of patients experience recurrence for reasons that remain unclear. Recurrence is associated with chemoresistance to carboplatin and paclitaxel and consequentially, high mortality. Understanding the pathways involved in endometrial cancer chemoresistance is paramount for the identification of biomarkers and novel molecular targets for this disease. Here, we generated the first matched pairs of carboplatin-sensitive/carboplatin-resistant and paclitaxel-sensitive/paclitaxel-resistant endometrial cancer cells and subjected them to bulk RNA sequencing analysis. We found that 45 genes are commonly upregulated in carboplatin- and paclitaxel-resistant cells as compared to controls. Of these, the leukemia inhibitory factor, (LIF), the protein tyrosine phosphatase type IVA, member 3 (PTP4A3), and the transforming growth factor beta 1 (TGFB1) showed a highly significant correlation between expression level and endometrial cancer overall survival (OS) and can stratify the 545 endometrial cancer patients in the TCGA cohort into a high-risk and low-risk-cohorts. Additionally, four genes within the 45 upregulated chemoresistance-associated genes are ADAMTS5, MICAL2, STAT5A, and PTP4A3 codes for proteins for which small-molecule inhibitors already exist. We identified these proteins as molecular targets for chemoresistant endometrial cancer and showed that treatment with their correspondent inhibitors effectively killed otherwise chemoresistant cells. Collectively, these findings underline the utility of matched pair of chemosensitive and chemoresistant cancer cells to identify markers for endometrial cancer risk stratification and to serve as a pharmacogenomics model for identification of alternative chemotherapy approaches for treatment of patients with recurrent disease.

AB - Despite advances in surgical technique and adjuvant treatment, endometrial cancer has recently seen an increase in incidence and mortality in the USA. The majority of endometrial cancers can be cured by surgery alone or in combination with adjuvant chemo- or radiotherapy; however, a subset of patients experience recurrence for reasons that remain unclear. Recurrence is associated with chemoresistance to carboplatin and paclitaxel and consequentially, high mortality. Understanding the pathways involved in endometrial cancer chemoresistance is paramount for the identification of biomarkers and novel molecular targets for this disease. Here, we generated the first matched pairs of carboplatin-sensitive/carboplatin-resistant and paclitaxel-sensitive/paclitaxel-resistant endometrial cancer cells and subjected them to bulk RNA sequencing analysis. We found that 45 genes are commonly upregulated in carboplatin- and paclitaxel-resistant cells as compared to controls. Of these, the leukemia inhibitory factor, (LIF), the protein tyrosine phosphatase type IVA, member 3 (PTP4A3), and the transforming growth factor beta 1 (TGFB1) showed a highly significant correlation between expression level and endometrial cancer overall survival (OS) and can stratify the 545 endometrial cancer patients in the TCGA cohort into a high-risk and low-risk-cohorts. Additionally, four genes within the 45 upregulated chemoresistance-associated genes are ADAMTS5, MICAL2, STAT5A, and PTP4A3 codes for proteins for which small-molecule inhibitors already exist. We identified these proteins as molecular targets for chemoresistant endometrial cancer and showed that treatment with their correspondent inhibitors effectively killed otherwise chemoresistant cells. Collectively, these findings underline the utility of matched pair of chemosensitive and chemoresistant cancer cells to identify markers for endometrial cancer risk stratification and to serve as a pharmacogenomics model for identification of alternative chemotherapy approaches for treatment of patients with recurrent disease.

KW - Chemoresistance

KW - Endometrial cancer

KW - Gene expression

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85049090447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049090447&partnerID=8YFLogxK

U2 - 10.1007/s12672-018-0337-6

DO - 10.1007/s12672-018-0337-6

M3 - Article

VL - 9

SP - 326

EP - 337

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 5

ER -